HHS is reviving a rebate program for 340B drug discounts after the previous pilot was blocked in court earlier this year. Providers say the change will burden already cash-strapped providers with new administrative and financial costs.
The funding, led by former Genzyme CEO Henri Termeer, funds the development of an immunomodulator that could be used for multiple sclerosis, type 1 diabetes, psoriasis and other autoimmune disease.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.